Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL19461055 | 0.94 | HSD17B10 (0.41) | HSD17B10SLC6A9CHRM5CHRM3S1PR1 | |
| Glutamic Acid SCHEMBL19461385 | 0.83 | GRM8 (0.51) | HSD17B10 | |
| SCHEMBL472213 | 0.80 | CHRM5 (0.50) | HSD17B10SLC6A9CHRM5CHRM3SIGMAR1 | |
| SCHEMBL29299554 | 0.80 | CHRM5 (0.50) | HSD17B10SLC6A9CHRM5CHRM3SIGMAR1 | |
| SCHEMBL306395 | 0.80 | CHRM5 (0.50) | HSD17B10SLC6A9CHRM5CHRM3SIGMAR1 | |
| Tetraxetan SCHEMBL2635294 | 0.79 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1TSHR | |
| SCHEMBL321989 | 0.79 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1TSHR | |
| Tetraxetan SCHEMBL18018 | 0.79 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1TSHR | |
| SCHEMBL6848102 | 0.79 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1TSHR | |
| SCHEMBL173508 | 0.79 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111511728-B | Compound for separating rare earth elements and s, p, d metals, separation method and use thereof | 有机生物化学公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4076541-A1 | MODIFIED GRPR ANTAGONIST PEPTIDES FOR IMAGING AND THERAPY OF CANCER | Technische Universität München (DE) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021126989-A1 | TWO-WAY MAGNETIC RESONANCE TUNING NANOPROBE ENHANCED SUBTRACTION IMAGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021121734-A1 | MODIFIED GRPR ANTAGONIST PEPTIDES FOR IMAGING AND THERAPY OF CANCER | Technische Universität München (DE) | 2021-06-24 | — | — | WO | disclosed |
| US-20090104124-A1 | Paramagnetic Complexes with Pendant Crown Compounds Showing Improved Targeting- Specificity as MRI Contrast Agents | UNIVERSITY HONG KONG, THE (CN) | 2009-04-23 | — | — | US | disclosed |
| US-7504088-B2 | Lipophilic derivatives of chelate monoamides | KEREOS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1768558-A1 | LIPOHILIC DERIVATIVES OF CHELATE MONOAMIDES | KEREOS, INC. (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006029560-A1 | PARAMAGNETIC COMPLEXES WITH PENDANT CROWN COMPOUNDS SHOWING IMPROVED TARGETING-SPECIFICITY AS MRI CONTRAST AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2006-03-23 | — | — | WO | disclosed |
| US-20060057071-A1 | Paramagnetic complexes with pendant crown compounds showing improved targeting-specificity as MRI contrast agents | UNIVERSITY OF HONG KONG, THE (CN) | 2006-03-16 | — | — | US | disclosed |
| US-20060008417-A1 | Lipophilic derivatives of chelate monoamides | KEREOS, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005122891-A1 | LIPOPHILIC DERIVATIVES OF CHELATE MONOAMIDES | KEREOS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060057071-A1 | Paramagnetic complexes with pendant crown compounds showing improved targeting-specificity as MRI contrast agents | ABCB11, ATP6V1B1, SLC5A7 | HSD17B10 3784/4885SLC6A9 291/4885CHRM5 3372/4885 |
| US-20060008417-A1 | Lipophilic derivatives of chelate monoamides | HDAC3, SGMS2, SGMS1 | HSD17B10 4678/4885SLC6A9 3236/4885CHRM5 23/4885 |
| US-20090104124-A1 | Paramagnetic Complexes with Pendant Crown Compounds Showing Improved Targeting- Specificity as MRI Contrast Agents | ABCB11, ATP6V1B1, SLC5A7 | HSD17B10 3784/4885SLC6A9 291/4885CHRM5 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.